Impact News +++ CECO Environmental Nears $2.2 Billion Deal for Thermon (Bloomberg) +++ THERMON Aktie +15,84%

BIOMARIN Aktie

>BIOMARIN Aktienkurs

52.1 EUR -2.1% (TradegateBSX)

Ask: 52.26 EUR / 108 Stück

Bid: 51.76 EUR / 109 Stück

Tagesumsatz: 80 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIOMARIN Aktie über LYNX handeln

Intraday

1 Jahr

>BIOMARIN Performance

1 Woche: +8,4%

1 Monat: +13,3%

3 Monate: +16,7%

6 Monate: +9,5%

1 Jahr: -17,6%

laufendes Jahr: +6,6%

>BIOMARIN Aktie

Name:

BIOMARIN PHAR. DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09061G1013 / 924801

Symbol/ Ticker:

BM8 (Frankfurt) / BMRN (NASDAQ)

Kürzel:

FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN

Index:

Webseite:

https://www.biomarin.com/

Profil:

BioMarin Pharmaceutical Inc. is a leading biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic diseases. Established in 1997 and headqua..
>Volltext..

Marktkapitalisierung:

10446.33 Mio. EUR

Unternehmenswert:

9708.66 Mio. EUR

Umsatz:

2617.86 Mio. EUR

EBITDA:

796.09 Mio. EUR

Nettogewinn:

441.6 Mio. EUR

Gewinn je Aktie:

2.31 EUR

Schulden:

518.63 Mio. EUR

Liquide Mittel:

1060.79 Mio. EUR

Operativer Cashflow:

775.56 Mio. EUR

Bargeldquote:

1.85

Umsatzwachstum:

6.57%

Gewinnwachstum:

53.21%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOMARIN

Letzte Datenerhebung:

24.02.26

>BIOMARIN Kennzahlen

Aktien/ Unternehmen:

Aktien: 192.11 Mio. St.

Frei handelbar: 98.51%

Leerverk. Aktien: 4.12%

Rückkaufquote: -0.13%

Mitarbeiter: 3040

Umsatz/Mitarb.: 0.79 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 38.04%

Bewertung:

KGV: 23.87

KGV lG: 28.86

KUV: 3.7

KBV: 2.02

PEG-Ratio: 0.37

EV/EBITDA: 12.2

Rentabilität:

Bruttomarge: 80.64%

Gewinnmarge: 16.87%

Operative Marge: 27.73%

Managementeffizenz:

Gesamtkaprendite: 7.2%

Eigenkaprendite: 9.07%

>BIOMARIN Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>BIOMARIN Chart & Kurs - NASDAQ

>BIOMARIN News

24.02.26 - 05:18	BioMarin signals $3.325B–$3.425B 2026 revenue target as acquisitions and pipeline drive growth (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.02.26 - 03:15	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
	BioMarin (BMRN) delivered earnings and revenue surprises of +85.48% and +5.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

24.02.26 - 03:15	Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics (Zacks)
	Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

24.02.26 - 00:01	BioMarin verfehlt Gewinnprognose für Q4 2025 – Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 23:24	BioMarin Pharmaceutical Posts Q4 Loss (AFX)
	WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Monday reported fourth-quarter net loss of $47 million or $0.24 per share, compared to net income of $125 million or $0.64 per share last......

23.02.26 - 22:21	Earnings Summary: BioMarin Pharmaceutical Q4 (Benzinga)
	Importance Rank: 1 read more...

23.02.26 - 22:15	BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.10, revenue of $875M beats by $39.97M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 22:09	BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results (PR Newswire)
	Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGO......

23.02.26 - 19:00	Amicus′ Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
	FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion....

20.02.26 - 23:36	BioMarin Pharmaceutical Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.02.26 - 16:45	Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics (Zacks)
	Besides Wall Street's top-and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025....

18.02.26 - 23:33	Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates \| DelveInsight (PR Newswire)
	With several potential therapies, including Sepiapterin (PTC Therapeutics), NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the phenylketonuria treatment landscape is expected to undergo substantial transformation between 2025 and 2034.......

16.02.26 - 22:01	What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
	Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week....

12.02.26 - 22:06	BioMarin Announces Closing of Private Offering of Senior Notes (PR Newswire)
	SAN RAFAEL, Calif., Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%.......

12.02.26 - 14:02	Positive Studiendaten von BridgeBio belasten Aktien von BioMarin und Ascendis (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 16:00	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
	FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion....

31.01.26 - 11:12	Should You Buy BioMarin Pharmaceutical Before Feb. 18? (Fool)
	There's no need to hurry in buying this biotech stock....

29.01.26 - 22:18	BioMarin prices $850M senior notes, completes $2B term loan syndication (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.01.26 - 22:09	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility (PR Newswire)
	SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%.......

28.01.26 - 19:00	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
	Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Nahe bei Hofe, nahe bei der Hölle. - Sprichwort Deutschland

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram